ArticlePakistan journal of medical sciences2025
Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D).
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with type II diabetes (T2D). Methods: This multicenter, retrospective study collected real-world data from various public & private hospitals, and primary care clinics in Pakistan. The total duration of clinical data collection was six months (April and September 2022) from 183 diabetic patients across different centers in Pakistan. Patients who had received IDegLira in combination with basal/premixed insulin, OHAs, or both regimes (basal/premixed insulin and OHAs) for the treatment of Type-II diabetes (T2D) in the Pakistani population were analyzed. Results: After receiving IDegLira therapy for six months, mean HbA1c was reduced by -1.1%, mean body weight reduced by 1.2 kg, fasting blood glucose levels (mg/dl): 164.7 (±36.2) to 134.4 (±32.9)] and random blood sugar (mg/dl): 240.1 (±71.4) to 207.6 (±77.8)]. The mean IDegLira dose steps were 19.9 (±6.7) at initiation and 23.5 (±7.9) at follow-up. Overall, adverse events reported were generally related to gastrointestinal, and few were related to headache, fatigue, and hypoglycemia events. Conclusion: The values of HbA1c and body weight decreased for the patients after using iDeglira for six months. Therefore, the medicine had a positive impact on the outcome of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.